Interview with Richard de Souza, CEO, Martindale Pharma
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
Address: Unit 6 Regents Drive,
Low Prudhoe Industrial Estate, Northumberland.
NE42 6PX.,United Kingdom
Tel: +44 (0) 1661 833 693
Web: www.scmpharma.com
SCM Pharma is a UK-based contract development and manufacturing organisation (CDMO) that develops and delivers novel, difficult and dangerous drugs on behalf of its clients. The company works with clients progressing drugs through the pre-clinical formulation stage, clinical trials and others that require low volume commercial supply of niche licensed products.
Privately-owned, SCM Pharma’s corporate HQ and MHRA-licensed manufacturing facilities are located in North East England with recently acquired additional laboratory space within the University of Sunderland’s state-of-the-art £8.5m science complex. Its clients include top 10 big pharma, speciality pharmaceutical companies, small biotech firms, virtual companies, public sector bodies and academic institutions from across Europe and North America.
With specific expertise in custom formulation, complex cGMP sterile manufacturing and aseptic filling, the award-winning CDMO is able to handle 14C radiolabeled compounds and potent products including cytotoxics. Its specialist offerings include –
• Process development
• Formulation development
• Aseptic processing (using isolator technology)
• Non-aseptic processing followed by terminal sterilisation
• GMP filling of 14C radiolabeled compounds
• Fill/¬finish of highly potent products including cytotoxic and cytostatic formulations
• Drug/medical device fi¬lling and assembly
• In-house testing including sterility, endotoxin, microbiology and analytical chemistry
• ICH stability testing
• Clinical packaging and distribution
• QP release
SCM Pharma can fill liquids, gels and powders into a range of final dosage forms including ampoules, vials, cartridges, syringes, bottles.
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
As the global economic roller coaster continues to unfold, governments the world over have desperately been scrambling to find the right policies that will effectively clamp on the brakes to…
Given the global trend of clinical research increasingly being outsourced to emerging markets, such as Asia and Latin America, where does this leave historical hubs of clinical research such as…
What does the life sciences sector represent for the Scottish economy in terms of value and employment and how have these figures evolved over the last few years? The Scottish…
Within the global trend of increased economic pressures on the pharmaceutical industry, there has been a recent focus on growth in emerging markets. In this context, where does this leave…
Prior to your current position you served in a number of marketing and managerial roles including at Bayer and Sanofi-Synthelabo. What drove you to move from those larger generalized multinational…
Shire’s International Marketing to being COO of start-up medical device company, Medicsight. What about Ferring and your current role attracted you to take this job and what are you bringing…
A key milestone for Atlantic Healthcare was the deal with Isis Pharmaceuticals for alicaforsen in 2007. In 2008, alicaforsen acquired orphan drug status in the U.S.; in 2009, orphan status…
See our Cookie Privacy Policy Here
